002653 海思科
已收盘 04-30 15:00:00
资讯
新帖
简况
西藏智汇矿业冲击IPO,辽宁沈阳女富豪创办,2024年收入大幅下滑
格隆汇 · 05-02 04:09
西藏智汇矿业冲击IPO,辽宁沈阳女富豪创办,2024年收入大幅下滑
AACR“最新突破性研究”,君实、恒瑞、信达、再鼎、海思科等新药入选
Insight数据库 · 04-25
AACR“最新突破性研究”,君实、恒瑞、信达、再鼎、海思科等新药入选
仿制药概念股回调,科伦药业跌逾5%,华东医药、海思科、山河药辅跌逾4%。
金融界 · 04-25
仿制药概念股回调,科伦药业跌逾5%,华东医药、海思科、山河药辅跌逾4%。
图解海思科一季报:第一季度单季净利润同比减49.31%
证券之星 · 04-24
图解海思科一季报:第一季度单季净利润同比减49.31%
4月23日海思科跌6.14%,富国精准医疗混合A基金重仓该股
证券之星 · 04-23
4月23日海思科跌6.14%,富国精准医疗混合A基金重仓该股
海思科(002653)股东范秀莲质押480万股,占总股本0.43%
证券之星 · 04-22
海思科(002653)股东范秀莲质押480万股,占总股本0.43%
【海思科:股东质押480万股】海思科公告,公司股东范秀莲女士质押480万股,占其所持股份比例2.21%,占公司总股本比例0.43%。质押起始日为2025年4月21日,质押到期日为2028年4月18日或质权人办理完毕解除质押登记手续之日,质权人为国金证券资产管理有限公司。质押用途为自身生产经营。本次质押股份未负担重大资产重组等业绩补偿义务。截至公告披露日,范秀莲女士及其一致行动人所持质押股份为5871万股,占其所持股份比例22.60%,占公司总股本比例5.24%。
金融界 · 04-22
【海思科:股东质押480万股】海思科公告,公司股东范秀莲女士质押480万股,占其所持股份比例2.21%,占公司总股本比例0.43%。质押起始日为2025年4月21日,质押到期日为2028年4月18日或质权人办理完毕解除质押登记手续之日,质权人为国金证券资产管理有限公司。质押用途为自身生产经营。本次质押股份未负担重大资产重组等业绩补偿义务。截至公告披露日,范秀莲女士及其一致行动人所持质押股份为5871万股,占其所持股份比例22.60%,占公司总股本比例5.24%。
4月18日海思科跌5.53%,富国精准医疗混合A基金重仓该股
证券之星 · 04-18
4月18日海思科跌5.53%,富国精准医疗混合A基金重仓该股
海思科(002653)3月31日股东户数0.91万户,较上期减少27.83%
证券之星 · 04-12
海思科(002653)3月31日股东户数0.91万户,较上期减少27.83%
每周股票复盘:海思科(002653)2024年年报主营收入37.21亿元,归母净利润3.95亿元
证券之星 · 04-11
每周股票复盘:海思科(002653)2024年年报主营收入37.21亿元,归母净利润3.95亿元
3月11日海思科涨6.99%,富国精准医疗混合A基金重仓该股
证券之星 · 03-11
3月11日海思科涨6.99%,富国精准医疗混合A基金重仓该股
海思科(002653)股东范秀莲质押245万股,占总股本0.22%
证券之星 · 03-09
海思科(002653)股东范秀莲质押245万股,占总股本0.22%
海思科新提交“海思药业”商标注册申请
证券之星 · 03-08
海思科新提交“海思药业”商标注册申请
西藏海思科制药有限公司申请I类会议
金融界 · 03-05
西藏海思科制药有限公司申请I类会议
海思科(002653.SZ)拟定增募资不超13.65亿元 用于新药研发项目、补充流资
智通财经 · 02-27
海思科(002653.SZ)拟定增募资不超13.65亿元 用于新药研发项目、补充流资
海思科最新公告:拟定增募资不超13.65亿元 投于新药研发项目等
证券之星 · 02-27
海思科最新公告:拟定增募资不超13.65亿元 投于新药研发项目等
海思科(002653)股东范秀莲质押386万股,占总股本0.34%
证券之星 · 02-25
海思科(002653)股东范秀莲质押386万股,占总股本0.34%
2月21日海思科(002653)涨停分析:政策催化、技术突破、研发进展驱动
证券之星 · 02-21
2月21日海思科(002653)涨停分析:政策催化、技术突破、研发进展驱动
2月21日海思科涨停分析:创新药,健康中国,西藏概念概念热股
证券之星 · 02-21
2月21日海思科涨停分析:创新药,健康中国,西藏概念概念热股
公司概况
公司名称:
海思科医药集团股份有限公司
所属行业:
医药制造业
上市日期:
2012-01-17
主营业务:
海思科医药集团股份有限公司的主营业务是新药研发、生产制造、推广营销业务。公司的主要产品是创新药环泊酚注射液、苯磺酸克利加巴林胶囊、考格列汀片。海思科以“创新”为内核,获得了行业的高度认可,连续多年荣获“中国创新力医药企业”称号。在2022-2023年中国医药行业最具影响力榜单评选中,海思科荣膺四项殊荣,包括医药商业百强企业、医药制造业百强企业、自主创新先锋企业、守法诚信企业。2024年中国医药研发产品线荣获“最佳工业企业”奖项。
发行价格:
20.00
{"stockData":{"symbol":"002653","market":"SZ","secType":"STK","nameCN":"海思科","latestPrice":42.8,"timestamp":1745996616000,"preClose":42.9,"halted":0,"volume":2987300,"delay":0,"changeRate":-0.0023,"floatShares":536000000,"shares":1120000000,"eps":0.3127,"marketStatus":"已收盘","change":-0.1,"latestTime":"04-30 15:00:00","open":42.69,"high":43.59,"low":42,"amount":128000000,"amplitude":0.0371,"askPrice":42.95,"askSize":18,"bidPrice":42.8,"bidSize":11,"shortable":0,"etf":0,"ttmEps":0.3127,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":5,"adr":0,"adjPreClose":42.9,"symbolType":"stock","openAndCloseTimeList":[[1745976600000,1745983800000],[1745989200000,1745996400000]],"highLimit":47.19,"lowLimit":38.61,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1119917970,"isCdr":false,"pbRate":11.67,"roa":"--","peRate":136.872402,"roe":"1.13%","epsLYR":0.35,"committee":-0.181818,"marketValue":47932000000,"turnoverRate":0.0056,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2025-05-06。","floatMarketCap":22933000000},"requestUrl":"/m/hq/s/002653/wiki","defaultTab":"wiki","newsList":[{"id":"2532865770","title":"西藏智汇矿业冲击IPO,辽宁沈阳女富豪创办,2024年收入大幅下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2532865770","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532865770?lang=zh_cn&edition=full","pubTime":"2025-05-02 12:09","pubTimestamp":1746158993,"startTime":"0","endTime":"0","summary":"近期,一家位于西藏的矿业公司向港交所发起冲击。不过,受生产线调整的影响,智汇矿业在2024年的收入和净利润均有所下滑。地下矿场预期于2025年下半年进入商业运营阶段。值得注意的是,2024年收入同比下降了44.8%,导致净利润也大幅下滑,主要是由于暂停生产线以配合选矿厂两条生产线于2024年间的顺序升级。因此,尽管2024年平均售价有所上升,精矿总销量大幅下降。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/02120950093922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0077","BK0033","BK0188","BK0239","002653","BK0028"],"gpt_icon":0},{"id":"2530590202","title":"AACR“最新突破性研究”,君实、恒瑞、信达、再鼎、海思科等新药入选","url":"https://stock-news.laohu8.com/highlight/detail?id=2530590202","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530590202?lang=zh_cn&edition=full","pubTime":"2025-04-25 10:59","pubTimestamp":1745549974,"startTime":"0","endTime":"0","summary":"据不完全统计,今年有超过 120 家中国药企亮相 AACR 会议,带来了近 300 项新药研究结果。其中,更是有 24 项中国新药研究入选了 “Late-breaking Abstracts ”。君实将在此次大会上首次公布 JS015 的初步临床研究数据,这也是国内首个公布临床数据的 DKK1 抑制剂。安全性和一系列免疫相关的副作用是 CTLA-4 抗体研发中面临的一个挑战。Insight 数据库显示,全球目前仅有 1 款 FRα ADC 获批,即艾伯维/华东医药/武田的索米妥昔单抗。本次大会上,海思科将公布该药用于治疗 CRPC 的研究数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425180503a466a363&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425180503a466a363&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0405327494.USD","002653","LU2488822045.USD","BK0188","BK0028","BK0060","LU0405327148.USD","LU1064130708.USD","LU2148510915.USD","LU1328615791.USD","BK0077","BK0033","600276","BK0183","BK0012","LU2328871848.SGD","LU1064131003.USD","LU1969619763.USD","BK0196","BK0239"],"gpt_icon":0},{"id":"2530948029","title":"仿制药概念股回调,科伦药业跌逾5%,华东医药、海思科、山河药辅跌逾4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530948029","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530948029?lang=zh_cn&edition=full","pubTime":"2025-04-25 10:10","pubTimestamp":1745547028,"startTime":"0","endTime":"0","summary":"仿制药概念股回调,科伦药业跌逾5%,华东医药、海思科、山河药辅跌逾4%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/25101049864042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","002653","BK0033","000963","BK0187","LU1064131003.USD","BK0188","BK0209","BK0077","LU1064130708.USD","BK0183","BK0196","LU1969619763.USD","BK0028","BK0177","BK0060","LU2148510915.USD","002422","BK0132","LU2328871848.SGD","300452","BK0175"],"gpt_icon":0},{"id":"2530961134","title":"图解海思科一季报:第一季度单季净利润同比减49.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530961134","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530961134?lang=zh_cn&edition=full","pubTime":"2025-04-25 02:55","pubTimestamp":1745520957,"startTime":"0","endTime":"0","summary":"证券之星消息,海思科2025年一季报显示,公司主营收入8.92亿元,同比上升18.6%;归母净利润4661.19万元,同比下降49.31%;扣非净利润5033.99万元,同比上升69.25%;负债率40.59%,投资收益-1062.77万元,财务费用291.74万元,毛利率70.29%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042500001558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653"],"gpt_icon":0},{"id":"2529529021","title":"4月23日海思科跌6.14%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2529529021","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529529021?lang=zh_cn&edition=full","pubTime":"2025-04-23 16:31","pubTimestamp":1745397078,"startTime":"0","endTime":"0","summary":"证券之星消息,4月23日海思科跌6.14%,收盘报42.92元,换手率1.17%,成交量6.26万手,成交额2.74亿元。重仓海思科的前十大公募基金请见下表:该股最近90天内共有7家机构给出评级,买入评级7家;过去90天内机构目标均价为53.27。根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共48家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为37.46亿元,最新净值2.9019,较上一交易日上涨3.48%,近一年上涨35.9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042300028162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","BK0077","BK0239","BK0188","002653","BK0028"],"gpt_icon":0},{"id":"2529582648","title":"海思科(002653)股东范秀莲质押480万股,占总股本0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529582648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529582648?lang=zh_cn&edition=full","pubTime":"2025-04-22 22:18","pubTimestamp":1745331483,"startTime":"0","endTime":"0","summary":"证券之星消息,海思科4月22日公开信息显示,股东范秀莲向国金证券资产管理有限公司合计质押480.0万股,占总股本0.43%。质押详情见下表:截止本公告日,股东王俊民已累计质押股份9465.0万股,占其持股总数的23.69%,股东范秀莲已累计质押股份5871.0万股,占其持股总数的27.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042200038994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","BK0028","BK0077","002653","BK0239","BK0188"],"gpt_icon":0},{"id":"2529349372","title":"【海思科:股东质押480万股】海思科公告,公司股东范秀莲女士质押480万股,占其所持股份比例2.21%,占公司总股本比例0.43%。质押起始日为2025年4月21日,质押到期日为2028年4月18日或质权人办理完毕解除质押登记手续之日,质权人为国金证券资产管理有限公司。质押用途为自身生产经营。本次质押股份未负担重大资产重组等业绩补偿义务。截至公告披露日,范秀莲女士及其一致行动人所持质押股份为5871万股,占其所持股份比例22.60%,占公司总股本比例5.24%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529349372","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529349372?lang=zh_cn&edition=full","pubTime":"2025-04-22 15:57","pubTimestamp":1745308636,"startTime":"0","endTime":"0","summary":"海思科公告,公司股东范秀莲女士质押480万股,占其所持股份比例2.21%,占公司总股本比例0.43%。质押起始日为2025年4月21日,质押到期日为2028年4月18日或质权人办理完毕解除质押登记手续之日,质权人为国金证券资产管理有限公司。质押用途为自身生产经营。本次质押股份未负担重大资产重组等业绩补偿义务。截至公告披露日,范秀莲女士及其一致行动人所持质押股份为5871万股,占其所持股份比例22.60%,占公司总股本比例5.24%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/22155749747846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1258","BK0276","600109","BK0012","BK0028","BK0201","BK0183","002653","09983","BK1229","BK0188","BK1583","BK0033","BK0239","BK1542","BK0077"],"gpt_icon":0},{"id":"2528373980","title":"4月18日海思科跌5.53%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2528373980","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528373980?lang=zh_cn&edition=full","pubTime":"2025-04-18 16:25","pubTimestamp":1744964730,"startTime":"0","endTime":"0","summary":"证券之星消息,4月18日海思科跌5.53%,收盘报43.87元,换手率0.92%,成交量4.9万手,成交额2.17亿元。重仓海思科的前十大公募基金请见下表:该股最近90天内共有6家机构给出评级,买入评级6家;过去90天内机构目标均价为48.66。根据2024基金年报公募基金重仓股数据,重仓该股的公募基金共39家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为35.22亿元,最新净值2.741,较上一交易日上涨0.18%,近一年上涨30.65%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041800024196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0033","002653","BK0077","BK0239","BK0188"],"gpt_icon":0},{"id":"2526960308","title":"海思科(002653)3月31日股东户数0.91万户,较上期减少27.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526960308","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2526960308?lang=zh_cn&edition=full","pubTime":"2025-04-12 17:00","pubTimestamp":1744448436,"startTime":"0","endTime":"0","summary":"证券之星消息,近日海思科披露,截至2025年3月31日公司股东户数为9069.0户,较12月31日减少3498.0户,减幅为27.83%。在化学制药行业个股中,海思科股东户数低于行业平均水平,截至3月31日,化学制药行业平均股东户数为3.11万户。从股价来看,2024年12月31日至2025年3月31日,海思科区间涨幅为14.85%,在此期间股东户数减少3498.0户,减幅为27.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041200010508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","002653","BK0028","BK0188","BK0077","BK0239"],"gpt_icon":0},{"id":"2526464658","title":"每周股票复盘:海思科(002653)2024年年报主营收入37.21亿元,归母净利润3.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2526464658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2526464658?lang=zh_cn&edition=full","pubTime":"2025-04-12 04:21","pubTimestamp":1744402867,"startTime":"0","endTime":"0","summary":"截至2025年4月11日收盘,海思科报收于47.45元,较上周的42.72元上涨11.07%。本周,海思科4月11日盘中最高价报47.45元,股价触及近一年最高点。4月9日盘中最低价报37.65元。本周共计1次涨停收盘,无跌停收盘情况。海思科当前最新总市值531.4亿元,在化学制药板块市值排名8/152,在两市A股市值排名249/5143。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041200006754.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653"],"gpt_icon":0},{"id":"2518796809","title":"3月11日海思科涨6.99%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2518796809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518796809?lang=zh_cn&edition=full","pubTime":"2025-03-11 16:21","pubTimestamp":1741681304,"startTime":"0","endTime":"0","summary":"证券之星消息,3月11日海思科涨6.99%,收盘报35.95元,换手率1.2%,成交量6.45万手,成交额2.28亿元。重仓海思科的前十大公募基金请见下表:该股最近90天内共有5家机构给出评级,买入评级5家;过去90天内机构目标均价为40.91。根据2024基金年报公募基金重仓股数据,重仓该股的公募基金共39家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为35.22亿元,最新净值2.4526,较上一交易日上涨0.35%,近一年上涨16.99%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100028050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","BK0188","BK0239","BK0028","002653","BK0077"],"gpt_icon":0},{"id":"2518283372","title":"海思科(002653)股东范秀莲质押245万股,占总股本0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518283372","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518283372?lang=zh_cn&edition=full","pubTime":"2025-03-09 21:34","pubTimestamp":1741527297,"startTime":"0","endTime":"0","summary":"证券之星消息,海思科3月9日公开信息显示,股东范秀莲向国金证券股份有限公司合计质押245.0万股,占总股本0.22%。质押详情见下表:截止本公告日,股东王俊民已累计质押股份9465.0万股,占其持股总数的23.69%,股东范秀莲已累计质押股份5581.0万股,占其持股总数的25.68%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030900004124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653","BK0077","BK0033","BK0028","BK0239","BK0188"],"gpt_icon":0},{"id":"2518424825","title":"海思科新提交“海思药业”商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2518424825","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518424825?lang=zh_cn&edition=full","pubTime":"2025-03-09 05:19","pubTimestamp":1741468765,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日海思科医药集团股份有限公司新提交“海思药业”商标注册申请。商标申请详情如下:今年以来海思科医药集团股份有限公司新申请注册商标1件,截止目前公司共持有注册商标836件,另有13件商标尚在注册申请中。数据来源:企查查以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030900000115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","002653","BK0028","BK0188","BK0077","BK0239"],"gpt_icon":0},{"id":"2517920838","title":"西藏海思科制药有限公司申请I类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2517920838","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517920838?lang=zh_cn&edition=full","pubTime":"2025-03-06 06:18","pubTimestamp":1741213083,"startTime":"0","endTime":"0","summary":"西藏海思科制药有限公司,成立于2019年,位于山南市,是一家以从事医药制造业为主的企业。通过天眼查大数据分析,西藏海思科制药有限公司共对外投资了1家企业,参与招投标项目6次,知识产权方面有商标信息33条,专利信息175条,此外企业还拥有行政许可2个。主要股东信息显示,西藏海思科制药有限公司由海思科医药集团股份有限公司持股100%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/06061848551492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0028","BK0077","BK0188","BK1191","01477","BK0239","002653","BK1574","BK0033"],"gpt_icon":0},{"id":"2514280545","title":"海思科(002653.SZ)拟定增募资不超13.65亿元 用于新药研发项目、补充流资","url":"https://stock-news.laohu8.com/highlight/detail?id=2514280545","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514280545?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:06","pubTimestamp":1740657990,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海思科(002653.SZ)披露2025年度向特定对象发行A股股票预案,公司拟向不超过35名(含35名)特定投资者发行股票,数量不超过7000万股(含本数),发行价格不低于定价基准日前20个交易日公司股票交易均价的80%。此外,本次向特定对象发行股票募集资金总额不超过13.65亿元(含本数),扣除发行费用后的净额拟投资于新药研发项目、补充流动资金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002653","BK0028","BK0188","BK0077","BK0033","BK0239"],"gpt_icon":0},{"id":"2514805505","title":"海思科最新公告:拟定增募资不超13.65亿元 投于新药研发项目等","url":"https://stock-news.laohu8.com/highlight/detail?id=2514805505","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514805505?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:01","pubTimestamp":1740657671,"startTime":"0","endTime":"0","summary":"海思科公布2025年度向特定对象发行A股股票预案,本次向特定对象发行股票数量不超过70,000,000股(含本数),按目前公司总股本测算,不超过本次发行前总股本的30%。本次向特定对象发行股票募集资金总额不超过13.65亿元(含本数),扣除发行费用后的净额拟9.65亿元用于投资于新药研发项目,4亿元用于补充流动资金。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022700037040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0028","BK0077","002653","BK0033"],"gpt_icon":0},{"id":"2514209444","title":"海思科(002653)股东范秀莲质押386万股,占总股本0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514209444","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514209444?lang=zh_cn&edition=full","pubTime":"2025-02-25 21:46","pubTimestamp":1740491161,"startTime":"0","endTime":"0","summary":"证券之星消息,海思科2月25日公开信息显示,股东范秀莲向国金证券股份有限公司合计质押386.0万股,占总股本0.34%。质押详情见下表:截止本公告日,股东王俊民已累计质押股份9465.0万股,占其持股总数的23.69%,股东范秀莲已累计质押股份5336.0万股,占其持股总数的24.55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022500040540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","002653","BK0077","BK0188","BK0239","BK0028"],"gpt_icon":0},{"id":"2513925395","title":"2月21日海思科(002653)涨停分析:政策催化、技术突破、研发进展驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2513925395","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513925395?lang=zh_cn&edition=full","pubTime":"2025-02-21 15:52","pubTimestamp":1740124348,"startTime":"0","endTime":"0","summary":"证券之星消息,海思科2月21日涨停收盘,收盘价32.78元。该股于11点16分涨停,未打开涨停,截止收盘封单资金为1.09亿元,占其流通市值0.62%。2月21日的资金流向数据方面,主力资金净流入2695.29万元,占总成交额10.27%,游资资金净流出1651.69万元,占总成交额6.29%,散户资金净流出1043.6万元,占总成交额3.97%。近5日资金流向一览见下表:该股为创新药,健康中国,西藏概念概念热股,当日创新药概念上涨0.85%,健康中国概念上涨0.78%,西藏概念概念上涨0.76%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022100022836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002653","BK0033","BK0077","BK0239","BK0028"],"gpt_icon":0},{"id":"2513825253","title":"2月21日海思科涨停分析:创新药,健康中国,西藏概念概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2513825253","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513825253?lang=zh_cn&edition=full","pubTime":"2025-02-21 15:36","pubTimestamp":1740123362,"startTime":"0","endTime":"0","summary":"证券之星消息,海思科2月21日涨停收盘,收盘价32.78元。该股于11点16分涨停,未打开涨停,截止收盘封单资金为1.09亿元,占其流通市值0.62%。2月21日的资金流向数据方面,主力资金净流入2695.29万元,占总成交额10.27%,游资资金净流出1651.69万元,占总成交额6.29%,散户资金净流出1043.6万元,占总成交额3.97%。近5日资金流向一览见下表:该股为创新药,健康中国,西藏概念概念热股,当日创新药概念上涨0.85%,健康中国概念上涨0.78%,西藏概念概念上涨0.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022100020741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0033","06978","BK0239","BK0188","BK1161","002653","BK0028","159992","BK1574"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1746392142335,"stockEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.1254},{"period":"3month","weight":0.3421},{"period":"6month","weight":0.1773},{"period":"1year","weight":0.4316},{"period":"ytd","weight":0.2927}],"compareEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.017},{"period":"3month","weight":0.0087},{"period":"6month","weight":0.0021},{"period":"1year","weight":0.0561},{"period":"ytd","weight":-0.0217}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"海思科医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9072人(较上一季度减少27.81%)","perCapita":"59063股","listingDate":"2012-01-17","address":"西藏自治区山南市乃东区泽当镇三湘大道17号","registeredCapital":"111991万元","survey":" 海思科医药集团股份有限公司的主营业务是新药研发、生产制造、推广营销业务。公司的主要产品是创新药环泊酚注射液、苯磺酸克利加巴林胶囊、考格列汀片。海思科以“创新”为内核,获得了行业的高度认可,连续多年荣获“中国创新力医药企业”称号。在2022-2023年中国医药行业最具影响力榜单评选中,海思科荣膺四项殊荣,包括医药商业百强企业、医药制造业百强企业、自主创新先锋企业、守法诚信企业。2024年中国医药研发产品线荣获“最佳工业企业”奖项。","listedPrice":20},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海思科(002653)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海思科(002653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海思科,002653,海思科股票,海思科股票老虎,海思科股票老虎国际,海思科行情,海思科股票行情,海思科股价,海思科股市,海思科股票价格,海思科股票交易,海思科股票购买,海思科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海思科(002653)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海思科(002653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}